| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENTA | Common Stock | Purchase | $256,050 | +45,000 | +5.6% | $5.69 | 846,638 | 12 Feb 2025 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 5,142 shares, all of which related to a "sell to cover" transaction required to satisfy tax withholding obligations due as a result of settlement of a portion of a restricted stock unit award granted on November 23, 2022. The reporting person has paid to Enanta $13,861.92, representing the full amount of the profit realized in connection with the short-swing transaction. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.86, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote of this Form 4. |